Baseline demographic and clinical characteristics of the patients
| Characteristic . | Total (N = 42)* . |
|---|---|
| Median age (range), y | 56 (19-74) |
| Male sex | 22 (52) |
| Number of transplants | |
| 1 | 29 (93) |
| 2 | 3 (7) |
| Type of transplant | |
| Myeloablative | 18 (43) |
| Nonmyeloablative | 24 (57) |
| Type of donor | |
| Related | 17 (40) |
| Unrelated | 25 (60) |
| HLA matching of cell graft between donor and recipient | |
| Matched | 37 (88) |
| Partially matched | 5 (12) |
| Stem cell source | |
| Peripheral blood stem cell | 37 (88) |
| Bone marrow | 4 (10) |
| Cord blood | 1 (2) |
| Median time from transplant (range), mo | 25.7 (2.7-79.5) |
| Median time from transplant to diagnosis of cGVHD (range), mo | 7.6 (1.5-76) |
| Median time from initial cGVHD diagnosis (range), mo | 13.7 (1.1-63.2) |
| Steroid dependence of cGVHD | |
| Steroid-dependent cGVHD | 28 (67) |
| Steroid-refractory cGVHD | 6 (14) |
| Both | 8 (19) |
| Number of involved organs | |
| 1 | 6 (14) |
| 2 | 24 (57) |
| 3 | 9 (21) |
| ≥4 | 3 (7) |
| Involved organ | |
| Mouth | 36 (86) |
| Skin | 34 (81) |
| Gastrointestinal system | 15 (36) |
| Liver | 3 (7) |
| Lungs | 2 (5) |
| Median Karnofsky Performance Status Score (range) | 80 (60-100) |
| >80 | 17 (40) |
| 70-80 | 22 (52) |
| 60 | 3 (7) |
| Median prior lines of treatment of cGVHD (range) | 2 (1-3) |
| Mean prednisone dose at enrollment (range), mg/kg per day | 0.31 (0.1-1.3) |
| Prior therapies for cGVHD | |
| Corticosteroids | 42 (100) |
| Tacrolimus | 21 (50) |
| Extracorporeal photopheresis/PUVA photochemotherapy | 11 (26) |
| Rituximab | 11 (26) |
| Mycophenolate mofetil | 10 (24) |
| Cyclosporine | 8 (19) |
| Sirolimus | 7 (17) |
| Other immunosuppressants | 2 (5) |
| Characteristic . | Total (N = 42)* . |
|---|---|
| Median age (range), y | 56 (19-74) |
| Male sex | 22 (52) |
| Number of transplants | |
| 1 | 29 (93) |
| 2 | 3 (7) |
| Type of transplant | |
| Myeloablative | 18 (43) |
| Nonmyeloablative | 24 (57) |
| Type of donor | |
| Related | 17 (40) |
| Unrelated | 25 (60) |
| HLA matching of cell graft between donor and recipient | |
| Matched | 37 (88) |
| Partially matched | 5 (12) |
| Stem cell source | |
| Peripheral blood stem cell | 37 (88) |
| Bone marrow | 4 (10) |
| Cord blood | 1 (2) |
| Median time from transplant (range), mo | 25.7 (2.7-79.5) |
| Median time from transplant to diagnosis of cGVHD (range), mo | 7.6 (1.5-76) |
| Median time from initial cGVHD diagnosis (range), mo | 13.7 (1.1-63.2) |
| Steroid dependence of cGVHD | |
| Steroid-dependent cGVHD | 28 (67) |
| Steroid-refractory cGVHD | 6 (14) |
| Both | 8 (19) |
| Number of involved organs | |
| 1 | 6 (14) |
| 2 | 24 (57) |
| 3 | 9 (21) |
| ≥4 | 3 (7) |
| Involved organ | |
| Mouth | 36 (86) |
| Skin | 34 (81) |
| Gastrointestinal system | 15 (36) |
| Liver | 3 (7) |
| Lungs | 2 (5) |
| Median Karnofsky Performance Status Score (range) | 80 (60-100) |
| >80 | 17 (40) |
| 70-80 | 22 (52) |
| 60 | 3 (7) |
| Median prior lines of treatment of cGVHD (range) | 2 (1-3) |
| Mean prednisone dose at enrollment (range), mg/kg per day | 0.31 (0.1-1.3) |
| Prior therapies for cGVHD | |
| Corticosteroids | 42 (100) |
| Tacrolimus | 21 (50) |
| Extracorporeal photopheresis/PUVA photochemotherapy | 11 (26) |
| Rituximab | 11 (26) |
| Mycophenolate mofetil | 10 (24) |
| Cyclosporine | 8 (19) |
| Sirolimus | 7 (17) |
| Other immunosuppressants | 2 (5) |
Data are presented as n (%) unless indicated otherwise.
PUVA, psoralen and ultraviolet A.
Of the 43 patients who received ibrutinib, 1 patient was excluded from the analysis because of the presence of relapse of the underlying malignancy evident from laboratory assessments of blood drawn before the first dose, but not resulted until after treatment initiation.